Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

doi:10.1136/heartjnl-2017-312858

Editorial

. 2018 Jul;104(13):1053-1055.

doi: 10.1136/heartjnl-2017-312858. Epub 2018 Feb 14.

Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Amand F Schmidt^{1

2

3}, Lucy S Pearce⁴, John T Wilkins^{5

6}, Juan P Casas⁷, Aroon D Hingorani¹

Affiliations

¹ Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK.
² Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
³ Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
⁴ Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
⁵ Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁶ Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁷ Farr Institute of Health Informatics, University College London, London, UK.

PMID: 29444808
DOI: 10.1136/heartjnl-2017-312858

Editorial

Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Amand F Schmidt et al. Heart. 2018 Jul.

. 2018 Jul;104(13):1053-1055.

doi: 10.1136/heartjnl-2017-312858. Epub 2018 Feb 14.

Authors

Amand F Schmidt^{1

2

3}, Lucy S Pearce⁴, John T Wilkins^{5

6}, Juan P Casas⁷, Aroon D Hingorani¹

Affiliations

¹ Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK.
² Groningen Research Institute of Pharmacy, University of Groningen, Groningen, The Netherlands.
³ Division Heart and Lungs, Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
⁴ Department of Non-communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK.
⁵ Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁶ Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
⁷ Farr Institute of Health Informatics, University College London, London, UK.

PMID: 29444808
DOI: 10.1136/heartjnl-2017-312858

No abstract available

Keywords: acute myocardial infarction; coronary artery disease; meta-analysis; systemic review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. Schmidt AF, et al. Cochrane Database Syst Rev. 2017 Apr 28;4(4):CD011748. doi: 10.1002/14651858.CD011748.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Oct 20;10:CD011748. doi: 10.1002/14651858.CD011748.pub3. PMID: 28453187 Free PMC article. Updated.

Cited by

Genetic drug target validation using Mendelian randomisation.
Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, Tyl B, Chopade S, Faraway R, Zwierzyna M, Hingorani AD. Schmidt AF, et al. Nat Commun. 2020 Jun 26;11(1):3255. doi: 10.1038/s41467-020-16969-0. Nat Commun. 2020. PMID: 32591531 Free PMC article.
Biomedical consequences of elevated cholesterol-containing lipoproteins and apolipoproteins on cardiovascular and non-cardiovascular outcomes.
Schmidt AF, Joshi R, Gordillo-Marañón M, Drenos F, Charoen P, Giambartolomei C, Bis JC, Gaunt TR, Hughes AD, Lawlor DA, Wong A, Price JF, Chaturvedi N, Wannamethee G, Franceschini N, Kivimaki M, Hingorani AD, Finan C. Schmidt AF, et al. Commun Med (Lond). 2023 Jan 20;3(1):9. doi: 10.1038/s43856-022-00234-0. Commun Med (Lond). 2023. PMID: 36670186 Free PMC article.
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease.
Schmidt AF, Hunt NB, Gordillo-Marañón M, Charoen P, Drenos F, Kivimaki M, Lawlor DA, Giambartolomei C, Papacosta O, Chaturvedi N, Bis JC, O'Donnell CJ, Wannamethee G, Wong A, Price JF, Hughes AD, Gaunt TR, Franceschini N, Mook-Kanamori DO, Zwierzyna M, Sofat R, Hingorani AD, Finan C. Schmidt AF, et al. Nat Commun. 2021 Sep 24;12(1):5640. doi: 10.1038/s41467-021-25703-3. Nat Commun. 2021. PMID: 34561430 Free PMC article.
Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?
Weisshaar S, Zeitlinger M. Weisshaar S, et al. Drugs. 2018 Jun;78(8):799-808. doi: 10.1007/s40265-018-0915-5. Drugs. 2018. PMID: 29737499 Review.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- HighWire
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Affiliations

Cochrane corner: PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Miscellaneous